TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26304646

Group type: EXPERIMENTAL
Intervention: Knee confidence assessed using item Q3 of the Knee injury and Osteoarthritis Outcome Score
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Pain on walking
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Poor general health
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 220
Study: 26304866

Group type: EXPERIMENTAL
Intervention: Dabigatran treatment initiated within 24 hours of minor stroke, continued for 30 days.
Number of subjects: 53
Study: 26304872

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 10 mg/kg once per week (cohort A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 15 mg/kg once per week (cohort B)
Number of subjects: 85
Study: 26305021

Group type: EXPERIMENTAL
Intervention: Continuous infusion of levobupivacaine 0.5 % (2 ml/h for 48 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (2 ml/h for 48 hours)
Number of subjects: 0
Study: 26305790

Group type: EXPERIMENTAL
Intervention: Pelvic belts
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study: 26306290

Group type: EXPERIMENTAL
Intervention: Desmopressin (dDAVP) administered by intravenous infusion in saline, 30-60 min before and 24 h after surgical resection.
Number of subjects: 20
Study: 26306719

Group type: EXPERIMENTAL
Intervention: Physical recovery from critical illness at 12 months, defined as being alive with Short Form-36 physical function score of at least 10 points, and not 10 or more points below baseline.
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Mortality rates at different time points.
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Factors associated with physical recovery.
Number of subjects: 610
Study: 26306819

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3 monthly (PP3M)
Number of subjects: 0
Study: 26308175

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tenofovir with atazanavir/ritonavir
Number of subjects: 146
Study: 26308285

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes (TILs) therapy
Number of subjects: 0
Study: 26308596

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Daratumumab 8 mg/kg
Number of subjects: 72
Study: 26308635

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 585

Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 585
Study: 26308942

Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CDA deficiency
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CDA genetic analysis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of gemcitabine
Number of subjects: 120
Study: 26310525

Group type: EXPERIMENTAL
Intervention: Structured, holistic review of care needs delivered at home by a respiratory nurse 4 weeks post-discharge.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Semistructured interviews and group discussions with patients, carers, and professionals.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sensitive approaches that foster independence.
Number of subjects: 14
Study: 26310540

Group type: EXPERIMENTAL
Intervention: Latent iron deficiency (serum ferritin ≤75 ng/mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal iron status (serum ferritin >75 ng/mL)
Number of subjects: 90
Study: 26310596

Group type: EXPERIMENTAL
Intervention: Greater alcohol involvement (measured by drinks per week, maximum drinks per day, frequency of heavy drinking, AUDIT-C, and alcohol problems)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control for alternative sex-linked explanations (i.e., depression and drug use)
Number of subjects: 508
Study: 26310837

Group type: EXPERIMENTAL
Intervention: CC rate 100-120/min and CC depth ≥ 60 mm (without mattress deflection correction)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CC depth
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Deeper CC
Number of subjects: 104
Study: 26310975

Group type: EXPERIMENTAL
Intervention: RG7256 (200 mg QD to 2400 mg BID)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RG7256 (high dose levels >1200 mg BID)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RG7256
Number of subjects: 45
Study: 26311446

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 0
Study: 26311774

Group type: EXPERIMENTAL
Intervention: Ventral scene-selective area (upper visual field)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral scene-selective region (lower visual field)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional imaging studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivoxel response analysis
Number of subjects: 0
Study: 26312070

Group type: EXPERIMENTAL
Intervention: Vildagliptin added-on to metformin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glibenclamide added-on to metformin
Number of subjects: 50
Study: 26312164

Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir once-daily dosing regimens: 35/7 mg/kg for 10 to <15 kg, 600/100 mg for 15 to <30 kg, 675/100 mg for 30 to <40 kg, 800/100 mg for ≥40 kg.
Number of subjects: 0
Study: 26312852

Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g daily) for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g daily)
Number of subjects: 28
Study: 26312908

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 34198
Study: 26312919

Group type: EXPERIMENTAL
Intervention: Closed loop insulin delivery
Number of subjects: 40
Study: 26313170

Group type: EXPERIMENTAL
Intervention: Radiolabeled human serum albumin
Number of subjects: 10
Study: 26313245

Group type: EXPERIMENTAL
Intervention: Systemic mycophenolate mofetil (MMF)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Topical cyclosporine A (CsA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Topical tacrolimus
Number of subjects: 235
Study: 26313402

Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound (MFU)
Number of subjects: 52
Study: 26313445

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 60 mg once daily plus PEG-IFN 180 µg weekly and RBV 1,000-1,200 mg/day (weight-based) twice daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: PEG-IFN/RBV (placebo group)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) plus PEG-IFN/RBV
Number of subjects: 124
Study: 26313683

Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage 0
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage I
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage II
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage III
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Post-CRT pathologic stage ypT0N1-2
Number of subjects: 140
Study: 26314396

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26314624

Group type: EXPERIMENTAL
Intervention: 17D-204 yellow fever vaccine (Stamaril, Sanofi-Pasteur, Lyon, France), 8 vials of lyophilized vaccine, viral quantification, cloning and sequencing of C/prM/E region.
Number of subjects: 0
Study: 26314729

Group type: EXPERIMENTAL
Intervention: Oral glucose challenge
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Oral lipid challenge
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Comparison between lipid and glucose challenges
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 214
Study: 26314740

Group type: EXPERIMENTAL
Intervention: Standardized measurement of CRP levels with enhanced CT-scan if CRP exceeds 140 mg/L on postoperative day 3, 4, or 5.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postoperative monitoring (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized measurement of CRP levels.
Number of subjects: 0
Study: 26314822

Group type: EXPERIMENTAL
Intervention: Icatibant injection
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Icatibant injection (2 or 3 injections)
Number of subjects: 170
Study: 26315282

Group type: EXPERIMENTAL
Intervention: Dynamic leg extensor muscle power
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 190
Study: 26315448

Group type: EXPERIMENTAL
Intervention: Subclinical macular edema
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Clinical macular edema
Number of subjects: 194

Group type: COMPARATOR
Intervention: Diabetic eyes without macular edema
Number of subjects: 194

Group type: COMPARATOR
Intervention: Diabetic patients with normal OCT
Number of subjects: 194

Group type: COMPARATOR
Intervention: Healthy eyes
Number of subjects: 194
Study: 26315560

Group type: EXPERIMENTAL
Intervention: Subclinical macular edema in type 2 diabetic eyes with mild NPDR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Progression to clinical macular edema
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Microvascular disease activity (MA turnover ≥6)
Number of subjects: 48
Study: 26315712

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP) planned in patients with FN risk at or above 20% threshold.
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Factors considered by physicians when assessing FN risk.
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Standardized FN risk assessment.
Number of subjects: 944
Study: 26315732

Group type: EXPERIMENTAL
Intervention: Final Kissing Ballooning (FKB)
Number of subjects: 1901

Group type: COMPARATOR
Intervention: Non-Final Kissing Ballooning (non-FKB)
Number of subjects: 1901
Study: 26315740

Group type: EXPERIMENTAL
Intervention: CoreValve Evolut R TAVR system (26- or 29-mm valve)
Number of subjects: 60
Study: 26315743

Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis using 24 mg of tissue-plasminogen activator (t-PA) administered as 1 mg/h for 24 h with a unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters.
Number of subjects: 150
Study: 26315931

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapies (fludarabine/cyclophosphamide/rituximab)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapies (bendamustine/rituximab)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Chemotherapies without an antibody (fludarabine/cyclophosphamide)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Chemotherapies without an antibody (fludarabine)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Chemotherapies without an antibody (chlorambucil)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: At least one antibody-containing regimen
Number of subjects: 1558

Group type: COMPARATOR
Intervention: No antibody treatment
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Aggressive chemo(immuno)therapy combinations (e.g. cyclophosphamide/doxorubicin/vincristine/prednisone)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Single agent chemotherapy (e.g. fludarabine)
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: Standard chemoimmunotherapy (e.g. fludarabine/cyclophosphamide/rituximab)
Number of subjects: 1558
Study: 26315949

Group type: EXPERIMENTAL
Intervention: Spirometry and reversibility tests
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Follow-up investigation of newly defined obstructive pulmonary disease patients
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Comprehensive RESPECT database
Number of subjects: 3133
Study: 26315953

Group type: EXPERIMENTAL
Intervention: Baseline dynamic parameters (flexion/extension cone relative to a fixed C-7, center of rotation [COR], and range of motion arc relative to the COR)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Focal parameters including increased C-7 sagittal translation over T-1 (slip)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Sagittal slip at C-2 and C-4
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Reduced flexion/extension motion cones, more posterior COR, and smaller range of motion
Number of subjects: 110
Study: 26315967

Group type: EXPERIMENTAL
Intervention: Continuing TKI therapy after RECIST progression
Number of subjects: 123

Group type: COMPARATOR
Intervention: Discontinuation of TKI therapy after RECIST progression
Number of subjects: 123
Study: 26316262

Group type: EXPERIMENTAL
Intervention: Central medial femorotibial compartment cartilage thickness loss
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Central femur cartilage thickness loss
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Central tibia cartilage thickness loss
Number of subjects: 600

Group type: COMPARATOR
Intervention: Lateral femorotibial compartment cartilage thickness loss
Number of subjects: 600
Study: 26316385

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month
Number of subjects: 40
Study: 26316523

Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ST-segment elevation MI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Peak plasma troponin concentrations
Number of subjects: 80
Study: 26316557

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 26317543

Group type: EXPERIMENTAL
Intervention: MTKI treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SUMSCAN favorable patients
Number of subjects: 58
Study: 26317981

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study: 26318254

Group type: EXPERIMENTAL
Intervention: Verproside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verproside combined with IKK inhibitor (BAY11-7082)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verproside combined with TAK1 inhibitor (5z-7-oxozeaenol)
Number of subjects: 0
Study: 26318833

Group type: EXPERIMENTAL
Intervention: EUS-guided FNA biopsy of the muscularis propria
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EUS-guided FNA biopsy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Surgical full-thickness biopsy
Number of subjects: 11
Study: 26321198

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker implantation
Number of subjects: 526
Study: 26321472

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of FdCyd and THU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral (PO) administration of FdCyd after THU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot study in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of THU with FdCyd
Number of subjects: 0
Study: 26321501

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT studies (baseline, interim, post-CTRT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Baseline TLG
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ΔTLG post-CTRT
Number of subjects: 31
Study: 26321596

Group type: EXPERIMENTAL
Intervention: Aorfix endograft (EVAR)
Number of subjects: 0
Study: 26322311

Group type: EXPERIMENTAL
Intervention: Warmer conditions (26-27°C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control conditions (19-20°C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (gender comparison)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peripheral temperature (mediating effect)
Number of subjects: 20
Study: 26322512

Group type: EXPERIMENTAL
Intervention: Catheter-resistance monitoring
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined prediction model (change in resistance >8.8% or non-laminar result)
Number of subjects: 10
Study: 26323022

Group type: EXPERIMENTAL
Intervention: Additive-enhanced diet (phosphorus additives)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-additive diet (no phosphorus additives)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-phosphorus diet in mice
Number of subjects: 10
Study: 26323282

Group type: EXPERIMENTAL
Intervention: 1-h copeptin
Number of subjects: 1439

Group type: EXPERIMENTAL
Intervention: 1-h hs-cTnT
Number of subjects: 1439
Study: 26324051

Group type: EXPERIMENTAL
Intervention: Short messaging service (SMS) text messages used as workshop reminders, post-workshop message reinforcement, spiritual/motivational messages, and participant retention.
Number of subjects: 0
Study: 26324363

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg administered on a 7-days-on/7-days-off schedule
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (various doses from 0.5 to 12 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (various doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 12 mg daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 9 mg daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 10 mg on a 7-days-on/7-days-off schedule
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (starting at 4 mg daily)
Number of subjects: 65
Study: 26325106

Group type: EXPERIMENTAL
Intervention: Pimonidazole (administered intravenously 16-20 hours before surgery)
Number of subjects: 10
Study: 26327127

Group type: EXPERIMENTAL
Intervention: Combined coronary CT angiography (CTA) and myocardial CT perfusion (CTP)
Number of subjects: 90
Study: 26327481

Group type: EXPERIMENTAL
Intervention: Radiation dose to the thyroid (up to 0.2 Gy)
Number of subjects: 4338

Group type: EXPERIMENTAL
Intervention: Surgical or radiological splenectomy (>20 Gy to the spleen)
Number of subjects: 4338

Group type: EXPERIMENTAL
Intervention: High radiation doses (>5 Gy) to pituitary gland
Number of subjects: 4338

Group type: EXPERIMENTAL
Intervention: Nitrosourea chemotherapy
Number of subjects: 4338

Group type: EXPERIMENTAL
Intervention: Radiation dose to the thyroid
Number of subjects: 4338

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at time of interview >= 25 kg/m(2)
Number of subjects: 4338

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at time of interview < 25 kg/m(2)
Number of subjects: 4338
Study: 26327694

Group type: EXPERIMENTAL
Intervention: Carfilzomib (20S proteasome inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 19S proteasome regulator knockdown
Number of subjects: 0
Study: 26327916

Group type: EXPERIMENTAL
Intervention: HCEE academic sites
Number of subjects: 197

Group type: COMPARATOR
Intervention: CI sites
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both HCEE and CI sites
Number of subjects: 197
Study: 26329464

Group type: EXPERIMENTAL
Intervention: Structured counselling session by gynaecologists
Number of subjects: 1871
Study: 26330288

Group type: EXPERIMENTAL
Intervention: Adjunctive armodafinil 150 mg/day
Number of subjects: 399

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 399
Study: 26330414

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1937360
Study: 26330425

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6784
Study: 26330458

Group type: EXPERIMENTAL
Intervention: BQ788 (3 mg, single intralesional application)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BQ788 (cumulative dosage of 8 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BQ788 (cumulative dosage of 10 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: PBS (control lesions)
Number of subjects: 5
Study: 26331103

Group type: EXPERIMENTAL
Intervention: Tai Chi training for 6 months (in TC-naïve adults)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Long-term Tai Chi practice (in TC experts)
Number of subjects: 87
Study: 26331432

Group type: EXPERIMENTAL
Intervention: Bendamustine 75 mg/m² on days 1 and 2, lenalidomide 25 mg on days 1-21, dexamethasone 40 mg on days 1, 8, 15, and 22
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bendamustine, lenalidomide, and dexamethasone
Number of subjects: 71
Study: 26331768

Group type: EXPERIMENTAL
Intervention: elosulfase alfa 2.0 mg/kg/week for 52 weeks
Number of subjects: 15
Study: 26332545

Group type: EXPERIMENTAL
Intervention: Imetelstat (9.4 mg/kg body weight, intravenous infusion every 1 to 3 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 33
Study: 26332546

Group type: EXPERIMENTAL
Intervention: Imetelstat (7.5 or 9.4 mg/kg intravenously once a week)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 18
Study: 26332547

Group type: EXPERIMENTAL
Intervention: Takotsubo cardiomyopathy
Number of subjects: 1750
Study: 26332874

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 100
Study: 26333343

Group type: EXPERIMENTAL
Intervention: sNGAL ≥179 ng/mL at 6 hours
Number of subjects: 458

Group type: COMPARATOR
Intervention: sNGAL <179 ng/mL and sCr <0.3 mg/dL
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: sNGAL ≥179 ng/mL
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: sCr ≥0.3 mg/dL
Number of subjects: 458

Group type: COMPARATOR
Intervention: sNGAL <179 ng/mL and sCr increase <0.3 mg/dL
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: sNGAL ≥179 ng/mL and sCr increase <0.3 mg/dL
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: sCr increase ≥0.3 mg/dL
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours
Number of subjects: 458
Study: 26333941

Group type: EXPERIMENTAL
Intervention: Long-term Antiretroviral Therapy (ART)
Number of subjects: 334
Study: 26334219

Group type: EXPERIMENTAL
Intervention: VS-6063 (425 mg b.i.d.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: VS-6063 (300-425 mg b.i.d.)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: VS-6063 (various doses)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: VS-6063 (500-750 mg b.i.d.)
Number of subjects: 46
Study: 26334382

Group type: EXPERIMENTAL
Intervention: CTA-CTP
Number of subjects: 381

Group type: COMPARATOR
Intervention: CTA
Number of subjects: 381

Group type: COMPARATOR
Intervention: CTP
Number of subjects: 381